THANK YOU FOR SUBSCRIBING
THANK YOU FOR SUBSCRIBING
BERG’s extensive subject matter expertise further bolsters a researcher’s ability to obtain desirable, data-backed results through improved professional collaboration. Since the company’s inception, Dr. Narain and his partners are focused on advocating for a collaborative business model that ties in collective goals and efforts to bring forth unbiased, front-ended hypotheses when developing new drugs. “BERG was among the first to usher in an approach to discovery that supports clinical processes via patient data-generated hypotheses, which are then implemented into a disciplined, pharmaceutically-oriented validation process,” expresses Dr. Narain.We use computational data sciences to discriminate differential biology
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info